Electrophysiology Unit Clinica Montevergine, Mercogliano.
University of Campania 'Luigi Vanvitelli', Monaldi Hospital.
J Cardiovasc Med (Hagerstown). 2020 Mar;21(3):250-258. doi: 10.2459/JCM.0000000000000928.
Cardiac resynchronization therapy (CRT) is an established treatment in patients with heart failure and prolonged QRS duration. A biventricular device is implanted to achieve faster activation and more synchronous contraction of the ventricles. Despite the convincing effect of CRT, 30-40% of patients do not respond. We decided to investigate the role of multipoint pacing (MPP) in a selected group of patients with right ventricle (RV)-to-left ventricle (LV) intervals less than 80 ms that do not respond to traditional CRT.
We will enrol 248 patients in this patient-blinded, observational, clinical study aiming to investigate if MPP could decrease LV end-systolic volume (ESV) in patients with RV-to-LV interval less than 80 ms. MPP will be activated ON at implant in patients with RV-to-LV delay less than 80 ms and OFF in RV-to-LV at least 80 ms. At follow-up the activation of MPP will be related to CRT response. The primary study endpoint will be the responder rate at 6 months, defined as a decrease in LV ejection fraction, LV end-diastolic volume, LV end-systolic volume (LVESV) at least 15% from baseline. Secondary outcomes include 12 months relative percentage reduction in LVESV and a combined clinical outcome measure of response to CRT defined as the patient being alive, no hospitalization due to heart failure, and experiencing an improvement in New York Heart Association functional class (Composite-Score).
Reducing the nonresponder rate continues to be an important goal for CRT.If an increase in reverse remodelling can be achieved by MPP, this study supports the conduct of larger trials investigating the role of MPP on clinical outcomes in selected patients treated, right now, only with traditional CRT.
ClinicalTrials.gov, NCT02713308. Registered on 18 March 2016.
心脏再同步治疗(CRT)是心力衰竭和 QRS 持续时间延长患者的既定治疗方法。双心室装置被植入以实现心室更快的激活和更同步的收缩。尽管 CRT 的效果令人信服,但仍有 30-40%的患者没有反应。我们决定在一组对传统 CRT 没有反应的右心室(RV)至左心室(LV)间隔小于 80ms 的患者中,研究多点起搏(MPP)的作用。
我们将在这项患者盲法、观察性临床研究中招募 248 名患者,旨在研究 MPP 是否可以减少 RV-to-LV 间隔小于 80ms 的患者的 LV 收缩末期容积(ESV)。在 RV-to-LV 延迟小于 80ms 的患者中,MPP 将在植入时激活 ON,而在 RV-to-LV 至少 80ms 时则激活 OFF。在随访中,MPP 的激活将与 CRT 反应相关。主要研究终点是 6 个月时的应答率,定义为 LV 射血分数、LV 舒张末期容积、LV 收缩末期容积(LVESV)从基线至少下降 15%。次要结局包括 12 个月时 LVESV 的相对百分比降低和 CRT 反应的综合临床结局衡量标准,定义为患者存活、无心力衰竭住院且纽约心脏协会功能分级(综合评分)改善。
降低无反应率仍然是 CRT 的一个重要目标。如果 MPP 可以实现逆重构的增加,那么这项研究支持进行更大规模的试验,研究 MPP 在目前仅接受传统 CRT 治疗的选定患者中的临床结局作用。
ClinicalTrials.gov,NCT02713308。于 2016 年 3 月 18 日注册。